Replimune Group Inc. stocks have been trading down by 0 percent amid pivotal FDA-related immunotherapy trial developments driving investor focus
Click Here for a Millionaire's POV on Trading REPL
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- The FDA issued a Complete Response Letter for Replimune’s BLA for RP1 plus nivolumab in advanced unresectable cutaneous melanoma, saying the data are not adequate, well-controlled evidence of effectiveness.
- Shares of Replimune Group Inc. dropped nearly 64% premarket after the FDA rejection of lead therapy vusolimogene oderparepvec, sparking heavy-volume selling and sharp volatility.
- Following the FDA decision, Piper Sandler, BMO Capital, Leerink, Wedbush, JPMorgan, and Jefferies all downgraded REPL and slashed price targets, some as low as $1–$2.
- Management at Replimune said that without accelerated approval, RP1’s development is not viable and it will cut jobs and scale back U.S. manufacturing operations.
- Law firm Pomerantz LLP launched a securities-fraud investigation into Replimune after the FDA’s rejection and the roughly 64% collapse in the stock price.
Live Update At 14:04:20 EDT: On Friday, April 24, 2026 Replimune Group Inc. stock [OTC: REPL] is trending down by 0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Replimune Group Inc. is trading like a broken biotech story after the RP1 melanoma blowup, but the balance sheet still matters for traders. REPL has been crushed from the mid-$8s in early 2026/04 down into the low single digits. The latest daily data show REPL sliding from $5.94 on 2026/04/10 to $1.70 by 2026/04/13, then bouncing into the $2–$3 zone, closing near $2.45 on 2026/04/24. That’s a violent reset in market expectations.
Under the hood, Replimune is classic early-stage biotech: heavy losses, decent cash. The latest quarterly report shows a net loss of about $70.9M on research and development spending of $53.1M and G&A of $18.7M. Operating cash flow ran roughly -$66M, while free cash flow was about -$66.1M.
The good news for REPL is liquidity. Cash and equivalents were roughly $122.9M, with total cash and short-term investments around $269.1M. Current assets of $280.4M and current liabilities of $50.1M yield a strong current ratio near 5.6, giving Replimune runway. Debt looks modest relative to equity, with total liabilities around $123.1M versus equity of about $210.5M.
More Breaking News
- Texas Instruments Stock Jumps As Earnings Beat Fuels Upgrades
- RUM Stock Jumps As Northern Data AI Deal Takes Shape
- ELPW Stock Jumps As Volatility Draws Active Traders
- CAR Stock Rockets As Travel Chaos Fuels Rental Demand
For traders, that mix — big losses, still-solid cash, and a shattered pipeline thesis — sets up a classic high-volatility, headline-driven chart.
Why Traders Are Watching REPL After The FDA Shock
REPL is on every momentum trader’s radar because the entire story flipped in days. The core catalyst was the FDA’s Complete Response Letter on the biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced unresectable cutaneous melanoma. Regulators said the IGNYTE data were not adequate, well-controlled evidence of effectiveness. That is not a minor fix; it hits the foundation of Replimune Group Inc.’s lead program.
Once that CRL hit, the tape in REPL unraveled. The stock plunged about 19% on the first headlines, then collapsed roughly 64% premarket when traders digested that this was a thesis-breaking event, not a routine delay. On 2026/04/10, REPL closed at $4.76. By 2026/04/13, it printed lows near $1.50 before closing at $1.70. That is maximum pain territory where forced selling and panic often dominate.
Wall Street piled on. Wedbush cut Replimune from Outperform to Neutral and slashed its target from $19 to $2, calling out “significant risk” to the phase 3 program. BMO went further, cutting REPL to Underperform and trimming its target from $11 to $1, pointing to major misalignment with the FDA and the likelihood of a lengthy, costly new trial. JPMorgan dropped REPL to Underweight, openly expecting the stock to trade in the low single digits.
Jefferies downgraded Replimune from Buy to Hold, slicing its target from $13 to $2 after management said RP1 would not be developed without accelerated approval. That line matters. It tells traders that REPL is not treating this as a simple resubmission; the company’s growth engine is effectively stalled. With multiple firms, from Piper Sandler to Leerink and Wedbush, all slashing targets, sentiment around REPL is decisively bearish.
To make matters worse, law firm Pomerantz LLP announced a securities-fraud investigation tied to the 64% collapse and the FDA rejection. For short-term trading, that adds another layer of headline risk on top of already heavy volatility.
Conclusion
REPL now trades like a wounded biotech trying to find a new story. The company has cash and a strong current ratio, but the FDA’s rejection of RP1 plus nivolumab in melanoma stripped away the main value driver that many traders were banking on. Replimune Group Inc. itself has said that without accelerated approval, RP1’s development is not viable and it will cut jobs and shrink U.S. manufacturing. That is retrenchment, not expansion.
For active traders, this is where discipline matters. REPL has already shown huge intraday swings, with five-minute candles whipping between $2.39 and $2.78 on heavy volume. Sharp bounces are possible as shorts cover and dip buyers crowd in, but the backdrop — failed BLA, sweeping downgrades, and a fraud probe — means any rally is trading, not a safety net.
In Tim Sykes’ world, this is exactly the kind of chart you study hard before touching. As Tim likes to say, “Volatile stocks are great teachers if you respect the risk and cut losses quickly.” That ties directly into another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. With REPL, that mindset is essential. The story has changed, the risk is elevated, and the only edge comes from understanding the news, watching the price action, and treating every trade as a planned, research-driven move — not a hope-and-pray bet.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.